

# WALDER WYSS ADVISES +ND CAPITAL ON ITS EXIT FROM CELLPOINT BY SALE TO GALAPAGOS

*Posted on 27 June 2022*



Category: [Deal & transactions](#)

Tags: [Alice Vorburger](#), [Luc Defferrard](#), [Slider](#), [WalderWyss](#)



**+ND Capital** has exited Dutch cell therapy company CellPoint by sale to the Belgian biotech company Galapagos which has acquired CellPoint for \$131 million upfront and up to \$105 million in milestone payments.

As sole venture investor in CellPoint, a company dedicated to developing CAR-T therapies at the point-of-care, the sale underlines +ND Capital's success in Europe, being its second exit after Arctos Medical sale to Novartis.

Headquartered in California, +ND Capital is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences. Currently they have over \$500M under management and are currently investing our \$335M third fund.

[Walder Wyss](#) has advised +ND Capital through its entire investment and in the sale transaction. The legal team was led by partner **Luc Defferrard** (corporate/m&a, pictured) and included **Michael Kündig** (senior associate, corporate/m&a) and **Alice Vorburger** (associate, corporate/m&a).